淋巴畸形市场：现况分析与预测（2023-2030）

由于疾病治疗方法的发展取得进展，全球淋巴畸形市场规模预计将稳定成长约6.54%。 例如，2023 年 11 月，Palvella Therapeutics, Inc. 的 QTORIN 雷帕霉素用于治疗微囊性淋巴畸形，获得了美国食品和药物管理局 (FDA) 的突破性疗法认定。 在预测期内，多种因素正在推动市场成长，例如对淋巴畸形的认识提高和医疗保健领域投资的增加。 除此之外，淋巴畸形治疗效率的加速带来了有效的治疗程序，也推动了淋巴畸形市场的稳定发展。

根据应用，市场分为诊断和治疗。 由于淋巴管畸形病例数量不断增加，到2022年，诊断领域将占据全球淋巴管畸形市场的最大占有率。 因此，对诊断工具和服务的需求不断增长，以筛检和监测患者的此类併发症。 糖尿病视网膜病变市场以诊断领域为主，因为医疗保健系统优先考虑早期检测和干预，以促进受淋巴管畸形影响的患者的福祉。 技术创新、筛检项目的扩大以及新兴国家的市场扩张可能会在未来几年进一步推动这一领域的成长。 因此，从应用来看，诊断领域将在2022年占据较大的市场占有率。

根据最终用户，市场分为医院、诊所和其他。 由于人们对淋巴畸形的认识不断提高，预计诊所部分将在预测期内占据重要的市场占有率。 诊所通常作为提高患者和医疗保健专业人员对淋巴畸形认识的中心。 随着意识的提高，更多的患者寻求诊断和治疗，诊所就诊次数也随之增加。 诊所配备了超音波、MRI、淋巴闪烁扫瞄等先进的诊断工具和技术，可准确诊断淋巴管畸形。 透过提供个人化的治疗计划和支援服务，他们优先考虑以患者为中心的护理，并倾向于吸引更多患者。 因此，在预测期内，诊所类别在最终用户中将表现出更高的复合年增长率。

为了更瞭解淋巴管畸形的市场介绍，市场为北美（美国、加拿大、北美其他地区）、欧洲（德国、英国、法国、西班牙、义大利、欧洲其他地区）、亚太地区（中国） 、日本）、印度、亚太地区其他地区）以及世界其他地区。 由于淋巴畸形病例迅速增加、人们对淋巴畸形的认识不断提高以及引入创新治疗的举措和投资不断增加，北美在 2022 年目前的情况下将主导市场。 例如，总部位于美国的 Protara Therapeutics 于 2023 年 10 月在其 II 期 STARBORN-1 试验中开始给药，该试验旨在研究一种治疗儿科患者淋巴管畸形的潜在细胞疗法。 由于该地区病例数量不断增加，政府机构启动了淋巴畸形认识计画。 因此，依地区划分，北美将在 2022 年占据较大市场占有率。

市场的主要营运公司包括 Pfizer Inc.、Protara Therapeutics、Zydus Pharmaceuticals, Inc.、Palvella Therapeutics、Avalo Therapeutics, Inc.、Alkem Laboratories Ltd. 和 GLENMARK PHARMACEUTICALS LTD。

目录

第一章市场介绍

• 市场定义
• 主要目标
• 利害关係人
• 限制

第二章研究方法/先决条件

• 调查过程
• 调查方法
• 受访者简介

第三章市场总结

第 4 章执行摘要

第五章COVID-19对淋巴畸形市场的影响

第 6 章淋巴畸形市场收入，2020-2030

第 7 章市场洞察：依应用划分

• 诊断
• 处理中

第 8 章市场洞察：最终用户

• 医院
• 诊所
• 其他

第 9 章市场洞察：依地区

• 北美
  • 美国
  • 加拿大
  • 北美其他地区
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 亚太地区其他地区
• 其他领域

第十章淋巴畸形市场动态

• 市场驱动因素
• 市场问题
• 影响分析

第11章淋巴畸形的市场机会

第十二章淋巴畸形市场趋势

第十三章供需分析

• 需求方分析
• 供给面分析

第14章价值链分析

第15章竞争场景

• 竞争状况
  • 波特五力分析

第十六章公司概况

• Pfizer Inc.
• Protara Therapeutics
• Zydus Pharmaceuticals, Inc.
• Palvella Therapeutics
• Avalo Therapeutics, Inc.
• Alkem Laboratories Ltd.
• GLENMARK PHARMACEUTICALS LTD.

第十七章免责声明

Lymphatic malformations are a form of rare disorders which are non-malignant masses consisting of fluid-filled channels due to abnormal development of lymphatic systems. These malformations are usually seen in the head and neck region of the body. Lymphatic malformations can be massive in size and even smaller malformations can potentially cause functional impairment of nearby organs and disfigurement of affected areas. Innovations in drug development and a rising number of clinical trials are leading to the growth of the market. Several other factors, such as rising research & development activities, rising healthcare expenditure, rising regulatory support, and a surge in government collaborations & partnerships are also acting as drivers of lymphatic malformation globally.

The Lymphatic Malformations Market is expected to grow at a steady rate of around 6.54% owing to the rising therapeutic developments for treating the illness. For instance, in November 2023, Palvella Therapeutics, Inc. received the U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation to QTORIN rapamycin for the treatment of microcystic lymphatic malformations. Several factors, including increasing awareness regarding lymphatic malformation, and increased investments in healthcare departments are driving the market's growth during the forecast period. Apart from this, accelerated treatment efficiency of lymphatic malformation has resulted in effective treatment procedures which are also driving this market of lymphatic malformation at a steady rate.

Based on the application, the market is bifurcated into diagnosis and treatment. The diagnosis segment held the maximum share in the global market of lymphatic malformation in 2022 owing to the rising cases of lymphatic malformation. As a result, there is a growing demand for diagnostic tools and services to screen and monitor patients for such complications. The diagnosis segment in the diabetic retinopathy market dominated as healthcare systems prioritize early detection and intervention for the welfare of patients suffering from lymphatic malformations. Technological innovations, expanding screening programs, and market expansion in emerging economies will further drive the growth of this segment in the coming years. Thus, among the applications, the diagnosis segment held a significant market share in 2022.

Based on the end user, the market is categorized into hospitals, clinics, and others. The clinic segment is expected to hold a significant share of the market in the forecast period owing to the rising awareness regarding lymphatic malformations. Clinics often serve as hubs for raising awareness about lymphatic malformations among patients and healthcare professionals. As awareness increases, more patients seek diagnosis and treatment, leading to growth in clinic visits. They are equipped with advanced diagnostic tools and techniques, such as ultrasound, MRI, and lymphoscintigraphy, which can accurately diagnose lymphatic malformations. It prioritizes patient-centered care by offering personalized treatment plans and supportive services tends to attract more patients. Thus, the clinic category will witness a higher CAGR amongst end users during the forecast period.

For a better understanding of the market adoption of lymphatic malformation, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is dominating the market in the current scenario of 2022 due to the surge in cases of lymphatic malformation, rising awareness about lymphatic malformation, and rising initiatives and investments in introducing innovative therapies. For instance, in October 2023, U.S.-based Protara Therapeutics commenced dosing in its Phase II STARBORN-1 trial investigating its cell therapy candidate for the treatment of lymphatic malformations in pediatric patients. Government organizations are initiating lymphatic malformation awareness programs for the sake of the growing cases in the region. Thus, amongst regions, North America held a significant share of the market in 2022.

Some of the major players operating in the market include Pfizer Inc.; Protara Therapeutics; Zydus Pharmaceuticals, Inc.; Palvella Therapeutics; Avalo Therapeutics, Inc.; Alkem Laboratories Ltd.; GLENMARK PHARMACEUTICALS LTD.

TABLE OF CONTENTS

1MARKET INTRODUCTION

• 1.1.Market Definitions
• 1.2.Main Objective
• 1.3.Stakeholders
• 1.4.Limitation

2RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1.Research Process of the Lymphatic Malformations Market
• 2.2.Research Methodology of the Lymphatic Malformations Market
• 2.3.Respondent Profile

3MARKET SYNOPSIS

4EXECUTIVE SUMMARY

5IMPACT OF COVID-19 ON THE LYMPHATIC MALFORMATIONS MARKET

6LYMPHATIC MALFORMATIONS MARKET REVENUE (USD BN), 2020-2030F

7MARKET INSIGHTS BY APPLICATION

• 7.1.Diagnosis
• 7.2.Treatment

8MARKET INSIGHTS BY END USER

• 8.1.Hospitals
• 8.2.Clinics
• 8.3.Others

9MARKET INSIGHTS BY REGION

• 9.1.North America
  • 9.1.1.U.S.
  • 9.1.2.Canada
  • 9.1.3.Rest of North America
• 9.2.Europe
  • 9.2.1.Germany
  • 9.2.2.U.K.
  • 9.2.3.France
  • 9.2.4.Italy
  • 9.2.5.Spain
  • 9.2.6.Rest of Europe
• 9.3.Asia-Pacific
  • 9.3.1.China
  • 9.3.2.Japan
  • 9.3.3.India
  • 9.3.4.Rest of Asia-Pacific
• 9.4.Rest of World

10LYMPHATIC MALFORMATIONS MARKET DYNAMICS

• 10.1.Market Drivers
• 10.2.Market Challenges
• 10.3.Impact Analysis

11LYMPHATIC MALFORMATIONS MARKET OPPORTUNITIES

12LYMPHATIC MALFORMATIONS MARKET TRENDS

13DEMAND AND SUPPLY-SIDE ANALYSIS

• 13.1.Demand Side Analysis
• 13.2.Supply Side Analysis

14VALUE CHAIN ANALYSIS

15COMPETITIVE SCENARIO

• 15.1.Competitive Landscape
  • 15.1.1.Porters Fiver Forces Analysis

16COMPANY PROFILED

• 16.1.Pfizer Inc.
• 16.2.Protara Therapeutics
• 16.3.Zydus Pharmaceuticals, Inc.
• 16.4.Palvella Therapeutics
• 16.5.Avalo Therapeutics, Inc.
• 16.6.Alkem Laboratories Ltd.
• 16.7.GLENMARK PHARMACEUTICALS LTD.

17DISCLAIMER